Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Cash & Current Investments: 2020-2024

Historic Cash & Current Investments for Mereo BioPharma Group (MREO) over the last 5 years, with Dec 2024 value amounting to $69.8 million.

  • Mereo BioPharma Group's Cash & Current Investments fell 39.52% to $48.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $237.1 million, marking a year-over-year decrease of 13.48%. This contributed to the annual value of $69.8 million for FY2024, which is 21.56% up from last year.
  • As of FY2024, Mereo BioPharma Group's Cash & Current Investments stood at $69.8 million, which was up 21.56% from $57.4 million recorded in FY2023.
  • Over the past 5 years, Mereo BioPharma Group's Cash & Current Investments peaked at $127.1 million during FY2021, and registered a low of $30.1 million during FY2020.
  • Moreover, its 3-year median value for Cash & Current Investments was $68.2 million (2022), whereas its average is $65.1 million.
  • As far as peak fluctuations go, Mereo BioPharma Group's Cash & Current Investments skyrocketed by 321.77% in 2021, and later slumped by 46.36% in 2022.
  • Mereo BioPharma Group's Cash & Current Investments (Yearly) stood at $30.1 million in 2020, then soared by 321.77% to $127.1 million in 2021, then slumped by 46.36% to $68.2 million in 2022, then declined by 15.78% to $57.4 million in 2023, then rose by 21.56% to $69.8 million in 2024.